The Latest
FIS Harvard 2019

Biomedicine’s long and risky road

Startlingly few institutional investors have allocations to life sciences. An informal poll of 85 asset owners from 20 countries responsible for a combined $9 trillion assets under management gathered at the Fiduciary Investors’ Symposium at Harvard University, found only a tiny handful active in the sector. Yet allocating to biotech makes an important contribution to society - investing in the sector can help change lives.
Analysis

CalPERS sees opening in VC

California Public Employees’ Retirement System CIO Ted Eliopoulos revealed in an interview that the pension giant sees ‘an opening’ caused by private companies taking longer to list.
Private Equity

LPs can look beyond top in VC

The common refrain from limited partner investors is that they can’t access ‘top-tier’ VC funds, so they avoid them entirely. A look at the data reveals whether this belief is fact or fiction.
Analysis

Future Fund focuses on technology

The lessons learned from embedding ESG risk management processes into the Future Fund’s portfolio can be readily applied to helping the fund improve its risk management for technological change.
<1of2>